Q1 2024 AtriCure Inc Earnings Call Transcript
Key Points
- AtriCure Inc (ATRC) reported a strong start to 2024 with total revenue of $109 million, reflecting a 16% growth from the first quarter of 2023.
- Adjusted EBITDA increased nearly 50% in Q1 2024 compared to Q1 2023, indicating improved profitability.
- The company is seeing robust adoption of its EnCompass clamp, driving growth in open ablation product sales which were up 16.5% over Q1 2023.
- AtriCure Inc (ATRC) is expanding its global impact with international revenue up 21.5% on a reported basis and 21.1% on a constant currency basis compared to Q1 2023.
- The company is actively investing in innovation, with new product launches like cryoSPHERE Plus and upcoming AtriClip Flex Mini expected to be significant growth drivers.
- Despite overall growth, the company's minimally invasive appendage management products saw a decline, primarily due to a reduction in LARIAT system sales.
- AtriCure Inc (ATRC) faces increasing competition in the market, which could impact market share and pricing power.
- The company reported a loss per share of $0.28 in Q1 2024, compared to a loss per share of $0.14 in Q1 2023.
- There are ongoing trials and new product introductions which, while potentially beneficial, also add uncertainty and risk to the company's future performance.
- The need for extensive clinical trials and regulatory approvals for new products like the AtriClip Flex Mini and PFA technologies can delay market entry and impact short-term growth.
Good afternoon, and welcome to AtriCure's First Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes. (Operator Instructions)
I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments.
Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call (513) 644 4484 to have one e-mailed to you.
Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings. These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, future product approvals, clearances, reimbursement
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
